Genenta Science SPA banner

Genenta Science SPA
NASDAQ:GNTA

Watchlist Manager
Genenta Science SPA Logo
Genenta Science SPA
NASDAQ:GNTA
Watchlist
Price: 0.7299 USD 1% Market Closed
Market Cap: $14m

Genenta Science SPA
Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Genenta Science SPA
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
Genenta Science SPA
NASDAQ:GNTA
Cash
€2.5m
CAGR 3-Years
-59%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
Philogen SpA
MIL:PHIL
Cash
€30.6m
CAGR 3-Years
51%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Ulisse Biomed Spa
MIL:UBM
Cash
€1.1k
CAGR 3-Years
122%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genenta Science SPA
Glance View

Market Cap
14m USD
Industry
Biotechnology

Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.

GNTA Intrinsic Value
0.7786 USD
Undervaluation 6%
Intrinsic Value
Price $0.7299

See Also

What is Genenta Science SPA's Cash?
Cash
2.5m EUR

Based on the financial report for Dec 31, 2024, Genenta Science SPA's Cash amounts to 2.5m EUR.

What is Genenta Science SPA's Cash growth rate?
Cash CAGR 5Y
-34%

Over the last year, the Cash growth was -31%. The average annual Cash growth rates for Genenta Science SPA have been -59% over the past three years , -34% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett